---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-010022"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T07:59:36.331144+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bioventus Q4 net loss $44.9M; FY22 net loss $213.4M; removes $350M CartiHeal liabilities

## Summary
- Net sales Q4 $125.8M (-3.5% YoY); Pain Treatments down 25.4% on higher rebate claims.
- FY22 net loss $213.4M vs $9.6M income in 2021; includes $189.2M non-cash impairment.
- Adjusted EBITDA Q4 $15.2M vs $28.5M; FY22 $66.3M vs $80.8M.
- Settlement on Feb 28, 2023 removed $350M of CartiHeal liabilities; credit agreement amended for covenant relief.
- Cash $31.8M, debt $418.1M at Dec 31, 2022.

## SEC filing metadata
- accession: 0001628280-23-010022
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828023010022/0001628280-23-010022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828023010022/bvs-20230331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-010022
- JSON: https://secwatch.observer/filing/0001628280-23-010022.json
- Plain text: https://secwatch.observer/filing/0001628280-23-010022.txt

## Key facts
- Earnings Releases
  Bioventus Inc. reported financial results for the quarter and year ended December 31, 2022.
  - Period: the quarter and year ended December 31, 2022
  - Result: reported results
  source text: On March 31, 2023 , Bioventus Inc. (the Company) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000162828023010022/0001628280-23-010022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.